Non-MAOI antidepressant drugs and cognitive functions: a review.
Little is known about the effects of non-MAOI antidepressants on cognitive functions, despite their wide application to ambulant patients. Evidence from studies involving healthy volunteers suggests that differences exist between drugs, with imipramine, amitriptyline and mianserin being associated with the most marked detrimental effects. However, these findings have generally not been supported by the few studies using clinical populations, for which improvements in cognitive functions are often recorded following treatment. The reasons for this discrepancy are discussed, and the need for further research suggested.
D000639:Amitriptyline / Q000009:adverse effects; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007099:Imipramine / Q000009:adverse effects; D008803:Mianserin / Q000009:adverse effects; D009048:Motor Skills / Q000187:drug effects; D009627:Nomifensine / Q000009:adverse effects; D011930:Reaction Time / Q000187:drug effects; D014745:Viloxazine / Q000009:adverse effects
D000928:Antidepressive Agents; D000639:Amitriptyline; D009627:Nomifensine; D008803:Mianserin; D014745:Viloxazine; D007099:Imipramine